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Abstract
Background: Small non-coding regulatory RNAs control cellular functions at the transcriptional and post-transcriptional
levels. Oral squamous cell carcinoma is among the leading cancers in the world and the presence of cervical
lymph node metastases is currently its strongest prognostic factor. In this work we aimed at finding small RNAs
expressed in oral squamous cell carcinoma that could be associated with the presence of lymph node metastasis.
Methods: Small RNA libraries from metastatic and non-metastatic oral squamous cell carcinomas were sequenced
for the identification and quantification of known small RNAs. Selected markers were validated in plasma samples.
Additionally, we used in silico analysis to investigate possible new molecules, not previously described, involved in
the metastatic process.
Results: Global expression patterns were not associated with cervical metastases. MiR-21, miR-203 and miR-205
were highly expressed throughout samples, in agreement with their role in epithelial cell biology, but disagreeing
with studies correlating these molecules with cancer invasion. Eighteen microRNAs, but no other small RNA class,
varied consistently between metastatic and non-metastatic samples. Nine of these microRNAs had been previously
detected in human plasma, eight of which presented consistent results between tissue and plasma samples. MiR-31
and miR-130b, known to inhibit several steps in the metastatic process, were over-expressed in non-metastatic samples
and the expression of miR-130b was confirmed in plasma of patients showing no metastasis. MiR-181 and miR-296
were detected in metastatic tumors and the expression of miR-296 was confirmed in plasma of patients presenting
metastasis. A novel microRNA-like molecule was also associated with non-metastatic samples, potentially targeting
cell-signaling mechanisms.
Conclusions: We corroborate literature data on the role of small RNAs in cancer metastasis and suggest the
detection of microRNAs as a tool that may assist in the evaluation of oral squamous cell carcinoma metastatic
potential.
Background
Small noncoding RNAs are regulatory molecules that
have recently emerged as important players in several
aspects of cellular biology. They are approximately 18 to
30 nucleotides in length and act mostly through the in-
activation of complementary sequences. MicroRNAs
(miRNAs) and PIWI interacting RNAs (piRNA), for in-
stance, are involved in sequence-specific and chromatin-
dependent gene silencing [1]. A variety of small RNAs
have been identified to date and the list is continuously
growing, partly due to the advent of new sequencing
technologies [2, 3].
Among these molecules, miRNAs have been exten-
sively studied. MiRNAs reduce mRNA stability and/or
translation due to full or partial sequence complemen-
tarity within target mRNAs. They are transcribed as
large pri-miRNA, which are then folded into stem-loop
structures, and transported to the cytoplasm where they
undergo additional processing generating a double-
stranded RNA [4, 5]. In general, one of the two comple-
mentary RNA molecules will integrate the RNA-induced
silencing complex (RISC) and interact with miRNA com-
plementary sites within target transcripts [6]. Initially
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described by Ambros and colleagues in the model or-
ganism Caenorhabditis elegans [7], miRNAs have been
shown to modulate a broad range of molecular pro-
cesses involved in tissue homeostasis and, ultimately, in
the pathogenesis of human diseases, including cancer
[8, 9]. Despite consensus on the role of miRNAs in can-
cer development, the part they play in the metastatic
cascade is not well defined. A number of studies have
already addressed miRNAs that may regulate this multi-
step process (for a review see [10]), and the use of
miRNAs expression profile for the discrimination be-
tween metastasized and non-metastasized tumors can
be exemplified by a recent publication in which the ex-
pression level of two miRNAs discriminated between
nonmetastatic and metastatic testicular cancer [11].
More recently, genome-wide analysis following The
Cancer Genome Atlas [12], showed that changes in the
expression levels of other small non-coding RNAs are
also associated with cancer, with strong correlations
between RNA abundance and disease status [13].
Altogether, these results indicate the possible application
of such molecules as disease markers.
Head and neck squamous cell carcinomas (HNSCC)
arise from epithelial cells in the lining of the upper aero-
digestive tract, comprising the nasal cavity and paranasal
sinuses, the nasopharynx, larynx, pharynx, the oral cavity
and the oropharynx. HNSCC is one of the leading cancer
types by incidence worldwide, with approximately 500,000
new cases a year worldwide and a five-year survival rate of
about 40-50 % [14]. Tumors usually develop in men over
the age of 60 years and tobacco and alcohol consumption
are the most important risk factors [15, 16].
Oral squamous cell carcinoma (OSCC) is a deadly
disease and, when grouped with pharyngeal cancer, it is
the sixth most common cancer in the world [17]. This
tumor is particularly risky because in its early stages it
progresses without producing pain or symptoms that
might be readily recognized by the patient. It is usually
discovered when the cancer has metastasized to the
lymph nodes of the neck and at this stage its prognosis
is significantly worse than when it is caught in a local-
ized intra oral area. In fact, the presence of cervical
lymph node metastasis is considered the most significant
prognostic indicator of survival and disease recurrence
in patients with HNSCC, with an approximate decrease
in 50 % in 5-year survival rate [18]. Thus, markers that
could help in the identification of the metastatic pheno-
type could be of use to the clinical setting.
In this work we aimed at finding small RNAs ex-
pressed in OSCC that could be associated with the pres-
ence of lymph node metastasis. We selected patients
with tumors at early stage of development (T1 or T2)
with neck metastases, and later stage tumors (T3 or T4)
with no neck lymph node metastases for high-throughput
sequencing aiming at the quantification of small RNAs.
Selected markers were validated in plasma collected from
HNSCC patients before surgery and in additional tumor
samples at various pathological stages. The identification
of a biomarker in plasma is of great use to the clinical
practice due to the minimally invasive characteristic of this
kind of assay. Additionally, we used in silico analysis to in-
vestigate possible new molecules, not previously described,
involved in the metastatic process.
Results and discussion
Highly expressed MiRNAs are common to OSCC samples
despite TNM staging
The small RNA fraction of 18 OSCC was sequenced.
Clinical and pathological data associated with the sam-
ples are described in Table 1. Two groups of samples
were sequenced: small tumors (T1 and T2) presenting
lymph node metastasis at the time of diagnosis and lar-
ger tumors (T3 and T4), which were metastasis-free at
the time of diagnosis. The reasoning behind dividing
samples in these two groups was to minimize biological
variation within the groups and, possibly, to be able to
select stronger markers linked to the metastatic pheno-
type due to their earlier presence in the tumor progression
(i.e., in T1/T2N+ samples) or maybe a protective role due
to their presence in non-metastatic larger tumors.
Template RNA for library sequencing was either total
RNA or the small-RNA fraction, according to the avail-
ability in our specimen repository at the time of the
experiment. In order to evaluate differences in the
small-RNA fraction associated with the kind of RNA
template, we assessed the expression levels of two en-
dogenous controls (RNU48 and U6) in each sample.
Figure 1 shows that there were no significant differences
in the expression levels of these two molecules associ-
ated with total RNA or small-RNA fractions.
The total number of sequenced and mapped reads is
reported in Additional file 1. Our analysis of the sequen-
cing data followed the workflow depicted in Fig. 2. In total,
984 mature miRNAs were identified when all samples
were considered, regardless of the sequenced arm (i.e., 3p
or 5p) (Additional files 2 and 3). Concerning global
expression levels of miRNAs, no association with TNM
staging was observed (Fig. 3). However, metastatic
tumors (N+) seemed to be more heterogeneous in terms
of the expression of these small RNAs than non-
metastatic (N0) samples, as depicted by the dispersion
of samples in the PCA plot.
The 10 most expressed miRNAs corresponded to at
least 50 % of the total number of expressed miRNAs
(Additional files 4 and 5). MiR-21 and miR-205 were the
most expressed molecules in almost all samples. The
relative expression of miR-205, known to be mostly
expressed in squamous cells, has been previously addressed
Severino et al. BMC Medical Genomics  (2015) 8:31 Page 2 of 15
Table 1 Clinical data on patients selected for miRNA sequencing and for miRNA identification in plasma
Patient Site Gender Age (yr) Pathologic stage Sample Tissue type Experiment
p0040 OC-T Male 48 T4N0M0 microRNA Tumor A
p0151 OC-T Male 47 T3N0M0 microRNA Tumor A
p0291 OC-T Male 55 T4N0M0 Total RNA Tumor A
p0340 OC-FOM Male 51 T4N0M0 microRNA Tumor A
p0374 OC-T / OC-FOM Male 56 T1N2bM0 microRNA Tumor A
p0397 OC-FOM Male 59 T1N3M0 microRNA Tumor A
p0418 OC-T Female 64 T4N0M0 microRNA Tumor A
p1022 OC-T Male 44 T3N0M0 Total RNA Tumor A
p1125 OC-T Male 53 T3N0M0 microRNA Tumor A
p1231 OC-FOM Male 56 T1N2bM0 microRNA Tumor A
p1381 OC-FOM Male 70 T1N2bM0 microRNA Tumor A
p1642 OC-T Male 80 T1N1M0 microRNA Tumor A
p0012 OC-FOM Male 50 T1N1M0 Total RNA Tumor A
p0280 OC-FOM Male 52 T1N2bM0 Total RNA Tumor A
p0441 OC-T Male 54 T1N1M0 microRNA Tumor A
p0486 OC-T Male 56 T3N0M0 microRNA Tumor A
p0652 OC-FOM Male 63 T1N1M0 microRNA Tumor A
p0677 OC-FOM Male 58 T1N2bM0 microRNA Tumor A
p1_0250 OP-BT Male 52 T4aN2aM0 Total RNA Tumor B
p1_0301 OP-BT Male 51 T4N0M0 Total RNA Tumor B
p1_0076 OC-T Male 63 T2N2M0 Total RNA Tumor B
p1_0151 OC-T Male 65 T2N2cM0 Total RNA Tumor B
p2_0072 OC-T Male 53 T3N0M0 Total RNA Tumor B
p2_0021 OC-FOM Male 63 T3N0M0 Total RNA Tumor B
p2_0048 OC-FOM Male 52 T2N2bM0 Total RNA Tumor B
p1_0273 OP-BT Male 68 T1N3M0 Total RNA Tumor B
p2_0057 OC-FOM Male 59 T3N0M0 Total RNA Tumor B
p0057 OC-T Male 57 T4N1M0 microRNA Tumor B
p0273 OC-T Male 56 T4N1M0 microRNA Tumor B
p0015 OC-FOM Male 57 T4N1M0 microRNA Tumor B
p0113 OC-FOM Male 67 T4N0M0 microRNA Tumor B
p0166 OC-T Male 54 T4N0M0 microRNA Tumor B
p0335 OC-T Female 85 T4N0M0 microRNA Tumor B
p1_0046 OC-T Male 54 T4aN2cM0 microRNA Plasma C
p1_0105 OC-T Female 80 T4aN2cM0 microRNA Plasma C
p1_0134 OC-T Male 57 T3N2bM0 microRNA Plasma C
p1_0149 OC-T Male 60 T1N0M0 microRNA Plasma C
p1_0151 OC-T Male 65 T2N2cM0 microRNA Plasma C
p1_0328 OC-T Male 65 T2N0M0 microRNA Plasma C
p2_0020 OC-T Male 58 T2N0M0 microRNA Plasma C
p2_0025 OC-T Male 58 T2N1M0 microRNA Plasma C
p2_0068 OC-T Male 67 T1N0M0 microRNA Plasma C
p2_0072 OC-T Male 53 T3N0M0 microRNA Plasma C
p1_0025 OC-FOM Male 61 T4aN2cM0 microRNA Plasma C
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as a metastasis marker for HNSCC [19]. In our dataset,
however, the molecule is highly but ubiquitously
expressed and cannot, therefore, be considered a me-
tastasis marker.
Similarly, miR-21 has been previously associated with
metastatic tumors and a few mechanistic explanations
have been proposed: in hepatocarcinoma it was re-
ported to target the tumor suppressor gene RHOB [20],
in non-small cell lung cancer it promoted metastasis by
targeting PTEN, and in breast cancer miR-21 was asso-
ciated with low levels of TIMP-3 in metastatic samples
[21]. In squamous cell carcinomas, increased expres-
sion of miR-21 was observed in human tumors cha-
racterized by p53 mutations and distant metastasis, and
the augmented expression of miR-21, mediated by
active mTOR and Stat3 signaling, conferred increased
invasive properties to mouse keratinocytes in vitro and
in vivo [22]. Recently it was associated with cancer
invasion via the Wnt/β-Catenin pathway in a study
using an oral squamous cell carcinoma cell line [23]. In
the set of samples analyzed here we did not identify
differential expression of miR-21 between metastatic
and non-metastatic tumors, but rather miR-21 was the
most or the second most expressed molecule in almost
every sample. In a previous report we showed that
miR-21 and miR-205 were both highly expressed in
squamous cell carcinoma samples, cancer-free surgical
margins as well as in a cell line and normal oral kerati-
nocytes, with no marked differences in expression
levels [24].
Table 1 Clinical data on patients selected for miRNA sequencing and for miRNA identification in plasma (Continued)
p1_0049 OC-FOM Male 70 T4aN1M0 microRNA Plasma C
p1_0061 OC-FOM Male 50 T4aN2cM0 microRNA Plasma C
p1_0111 OC-FOM Male 55 T1N3M1 microRNA Plasma C
p1_0115 OC-FOM Male 56 T4aN2cM1 microRNA Plasma C
p1_0119 OC-FOM Male 50 T4bN3M0 microRNA Plasma C
p1_0220 OC-FOM Male 50 T1N0M0 microRNA Plasma C
p1_0236 OC-FOM Male 53 T4aN2bM0 microRNA Plasma C
p1_0248 OC-FOM Male 55 T2N2aM0 microRNA Plasma C
p1_0308 OC-FOM Male 50 T4aN0M0 microRNA Plasma C
p1_0323 OC-FOM Male 50 T4aN2cM0 microRNA Plasma C
p1_0335 OC-FOM Female 59 T2N0M0 microRNA Plasma C
p2_0021 OC-FOM Male 63 T3N0M0 microRNA Plasma C
p2_0031 OC-FOM Male 62 T1N2bM0 microRNA Plasma C
p2_0035 OC-FOM Male 57 T1N0M0 microRNA Plasma C
p2_0041 OC-FOM Male 64 T4aN0M0 microRNA Plasma C
p2_0048 OC-FOM Male 52 T2N2bM0 microRNA Plasma C
p2_0058 OC-FOM Male 58 T4N2bM0 microRNA Plasma C
p2_0062 OC-FOM Male 55 T1N0M0 microRNA Plasma C
p2_0095 OC-FOM Male 52 T3N2bM0 microRNA Plasma C
OC-T: Oral Cavity – Tongue, OC-FOM: Oral Cavity - Floor of the Mouth. Pathological Stage describes the metastatic status of the samples, with N0 meaning no
lymph node metastasis at the time of diagnosis and N > 0 indicating the presence of lymph node metastasis. Experiment description: A- tumor tissue samples
used for small RNA sequencing; B – tumor tissue sample used for miRNA expression validation by real-time PCR; C - plasma samples used for miRNA expression
detection by real-time PCR
Fig. 1 Expression levels of RNU48 and U6 in miRNA samples and total RNA samples used as input for the sequencing protocol. a: Expression
levels of RNU48; b: Expression levels of U6.
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Fig. 2 Workflow for sequencing data Analysis
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MiR-203, a marker of differentiated human keratino-
cytes, known to regulate keratinocyte proliferation and
regulation in adult epidermis [25, 26] and implicated in
cancer progression and metastasis [27, 28], was also
abundantly expressed in our samples.
Despite the role of miR-21, miR-203 and miR-205 in
cellular processes associated with cancer metastasis,
clearly demonstrated when each one is studied inde-
pendently, their concurrent importance in keratinocyte
physiology constitutes a drawback when studying them
in regard to proliferation and invasion in the context of
squamous cell carcinomas.
miRNAs as metastasis markers: evidences from tissue and
plasma samples
For the identification of miRNAs possibly involved in
the metastatic process we selected reads counted at least
10 times per sequenced sample and used the EdgeR
Bioconductor software package for data normalization
and differential expression analysis between metastatic
(N+) and non-metastatic (N0) samples. Table 2 lists
miRNAs that presented at least a 2-fold difference in
expression between the two groups and which were
regulated in at least half the samples from each group.
Two microRNAs were significantly more expressed in
N0 when compared to N+ samples: miR-31 and miR-
130b. In agreement with our data, miR-31 was previ-
ously described as a potent inhibitor of breast cancer
metastasis [29], and was also shown to impair breast
cancer-derived lung metastases through a specific
Fig. 3 PCA plot depicting global miRNA RNA expression in OSCC samples
Table 2 Differential miRNA expression between non-metastatic
and metastatic OSCC samples
Fold change (N0/N+) P value
hsa-mir-31-5p 3.33 2.02E-002
hsa-mir-130b-5p 3.04 3.14E-002
hsa-mir-301a-3p 2.29 1.06E-001
hsa-mir-1301 −2.07 1.89E-001
hsa-mir-551b-3p −2.10 1.60E-001
hsa-mir-345-5p −2.22 1.37E-001
hsa-mir-30a-5p −2.31 1.25E-001
hsa-mir-326 −2.32 1.18E-001
hsa-mir-769-5p −2.35 1.13E-001
hsa-mir-139-5p −2.40 1.02E-001
hsa-mir-218-5p −2.72 6.69E-002
hsa-mir-106a-5p −2.81 8.02E-002
hsa-mir-335-5p −3.56 2.16E-002
hsa-mir-296-5p −3.58 2.21E-002
hsa-mir-20b-5p −3.88 1.54E-002
hsa-mir-23c −4.98 4.83E-003
hsa-mir-1277-3p −9.82 1.80E-004
hsa-mir-181d-5p −10.01 1.66E-004
Positive Fold Change: higher expression in non-metastasized OSCC; negative
Fold Change: higher expression in metastasized OSCC. p-values were adjusted
using the False Discovery Rate (FDR) correction and adjusted p values < 0.05
are in bold in order to highlight statistical significance. The suffix 3p/5p indicate
which of the two arms of the miRNA was considered in the analysis, being either
exclusively expressed or predominantly expressed in the dataset (Additional files
2 and 3 present detailed information on the expression levels of each arm)
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mechanism targeting cell cycle arrest and apoptosis [30].
Higher levels of miR-31 expression in HNSCC when
compared to cancer-free tissue have been reported [24, 31]
but a potential role for miR-31 in HNSCC metastasis has
never been proposed.
MiR-130b was also found up regulated in HNSCC when
compared to cancer-free tissues [32, 24] and it is involved
in immortalization of normal oral keratinocytes [33]. Its
possible role in metastasis was recently demonstrated
when its over-expression decreased migration and inva-
sion in colorectal cancer cells [34]. Our data, thus, corrob-
orates the reported involvement of miR-31 and miR-130b
in metastasis and supports the their possible use as
molecular marker for non-metastatic cancer or as thera-
peutic molecules. Results for miR-130b and for miR-31
were confirmed in an additional set of 15 samples corre-
sponding to 8 metastatic and 7 non-metastatic tumors
of different pathological stages (Table 1). MiR-130b and
miR-31 presented 2.27 and 1.97 fold-change differences
in gene expression levels, respectively, when comparing
N0 and N+ samples (Additional file 6).
Six miRNAs were found to be up regulated in meta-
static OSCC with statistic significance (p < 0.05). The
most expressed molecule in N+ samples, miR-181, has
been previously associated with metastasis and, in fact, it
has been considered as a marker for lymph-node metastasis
in OSCC [35]. Another miRNA involved in metastatic pro-
cesses is miR-296, possibly through targeting ICAM-1 [36].
Corroborating the sequencing results, in the additional
set of 15 tumor samples miR-296 was over-expressed in
N+ samples (3.3 fold change, Additional file 6).
Besides the above-mentioned topics, little is known
about the involvement of the miRNAs identified here
and the metastatic cascade. Despite important results
when miRNAs are studied individually, considering the
complexity of miRNA regulatory networks, numerous
additional studies are still needed for a better under-
standing of the whole system.
However, for clinical application, a biomarker may be-
come useful without a full comprehension of its mech-
anistic role in the pathophysiology of a disease, in
particular if the biomarker can be readily assessed in
body fluids such as blood or saliva. The stability of
miRNAs in plasma has been demonstrated, including for
OSCC [37]. From our list of 18 miRNAs showing at least
a 2-fold difference in expression levels between N+ and
N0 samples and consistent expression in each of the
two groups, 9 had been detected in human plasma
during large scale screening studies [38, 39]. Thus, we
chose to evaluate their expression levels in plasma using
an additional set of 30 patients (Table 1). A comparison
between read counts from the sequencing approach and
real-time expression levels is not straight forward, but
Fig. 4 shows that, except for miR-551b, up or down regu-
lation considering N+ or N0 groups was consistent in tis-
sue and plasma.
Due to the reported role of miR-31 in inhibiting metasta-
sis, we addressed its expression in plasma despite the fact
that it had not been previously detected in human plasma
[38, 39]. As expected, we could not detect miR-31 in the
additional set of 30 OSCC patients (data not shown).
Cell-free microRNAs detected in plasma are of clinical
interest due to their possible application as non-invasive
biomarkers and literature reports on this possible appli-
cation is resonant (for a review see [40]). Despite the
large number of articles addressing the issue, most re-
sults lack validation.
Known small RNAs other than miRNA and their
contribution to the metastatic phenotype
Small RNAs other that miRNAs may also be implicated
in cancer progression/metastasis. Piwi-interacting RNA
Fig. 4 Expression levels in plasma of miRNAs differentially expressed between N+ and N0 tissue samples according to sequencing results. MiRNA
selected for this evaluation were those that had been previously detected in human plasma and showed differential expression between
metastatic and non-metastatic OSCC samples
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(piRNA) pathway, for instance, is known for its role in
germ cell maintenance and is currently being studied in
the context of cancer [41], and snoRNAs have also been
shown to contribute to oncogenesis [42].
In order to search for small RNAs other than miRNAs
in our dataset we used BLAST to match reads that did
not correspond to sequences deposited in miRBase
against a dataset containing sequences from public non-
coding RNA databases. A total of 197 reads had good
hits. Of these, 68 reads were associated with specific
ncRNA categories, in particular: piRNA (Piwi-interacting
RNA), snoRNA (small nucleolar RNA), snRNA (small
nuclear ribonucleic acid), Y RNA, easRNA (exon-associ-
ated small RNA), rasRNA (repeat-associated small RNA)
or pasRNA (promoter-associated small RNA) (Additional
file 7). The remaining reads had hits associated with anno-
tated sequences that did not specify the ncRNA type
(most of the original reads were annotated using ab initio
methods for detecting covariance) (Additional file 8).
The expression levels of these small RNAs are re-
ported in Additional file 9. Figure 5 shows that their ex-
pression was mostly homogeneous in our dataset, with
the exception of the non-metastatic sample p0151 and
the metastatic sample p1642, both tongue-derived
samples.
To our knowledge there is no published data on the
expression of small RNAs other than miRNAs and
HNSCC. We show that despite homogeneity in their
global expression, small RNAs other than miRNAs are
expressed and should exert a regulatory function associ-
ated with the cancer phenotype.
Identification of a putative miRNA molecule
The utilization of new sequencing technologies allows,
besides traditional analysis of gene expression analysis,
the possibility of identifying new molecules possibly
linked with a certain disease phenotype. In order to in-
vestigate new molecules in our dataset we selected reads
that showed no positive match with miRNAs and other
small RNAs but that mapped to the human genome and
that presented differential expression between N0 and N+.
In brief, we performed ab initio and structural search
based on putative precursors sequences constructed
from our sequenced reads, following the workflow
depicted in Fig. 1.
Table 3 shows the 7 best candidates considering ab
initio and structural search. There was variation in the
prediction depending on the position of the read in the
putative precursor since structural and ab initio classifi-
cation searches are influenced by nucleotide sequence
and the by the length of the sequence. Three reads had
positive classification only for C/D snoRNA. Considering
the reported specificity of snoReport (0.91 for the classi-
fication of C/D snoRNAs) and the high scores obtained
by the candidates, these sequences were annotated as
snoRNAs and were not further analysed.
If any of the remaining reads corresponded to a ma-
ture miRNA, it would most likely map within the stem
of the predicted structure. The only candidate that ful-
filled this criterium was 12375 (Fig. 6a). Additionally, as
a means to add to this structural prediction, we used
MatureBayes to find a putative mature sequence within
this structure, and the algorithm found one that mapped
Fig. 5 PCA plot depicting global small RNA expression in OSCC samples. For the clusterization of clinical samples based on the expression levels
of small RNAs other that miRNAs we used Principal Components Analysis (PCA). All annotated molecules were included in this analysis. Results
show that samples are very homogeneous concerning the expression of these small RNA molecules
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exactly within our sequenced read (Fig. 6b). A similarity
search against 3’UTR sequences of the human genome
allowed us to identify a possible target for this predicted
mature sequence, PLEKHA6 (pleckstrin homology do-
main containing, family A member 6) (Fig. 7). Candidate
12375 was mostly expressed in N0 samples, and could
possibly target PLEKHA6. Although there are no current
studies available for the role of PLEKHA6 protein, the
pleckstrin homology domain occurs is a variety of pro-
tein involved in intracellular signaling [43].
The identification of new miRNA molecules is not ob-
vious and several studies have published lists of novel
molecules based solely on structural prediction. Despite
the manually curated evidences shown here, we believe
functional studies are necessary in order to confirm this
assumption.
Noteworthy, the expression levels of the sequenced
read belonging to this molecule as well as to the other
predicted ones suggest a possible role for them in
OSCC, regardless of the RNA class they may belong to.
A
B
Fig. 6 MiRNA-candidate structure and mature sequence prediction. a: The structure predicted using RNAfold contains the sequence read within
the precursor stem (indicated by the arrows). This position suggests that the read could be processed into a mature miRNA; b: Prediction of a
mature miRNA molecule within our predicted structure according to MatureBayes. The sequenced read is in black bold and the mature sequence
predicted by MatureBayes is in bold red
Table 3 MiRNA-like molecules identified using structural search and ab initio prediction
Candidate
number
Ext Chr Start Position End Position Pred Length SnoReport
score
HMMiR
likelihood ratio
Fold-change
(N0/N+)
356 Both chr4 102,540,761 102,541,036 miRNA 276 0 0.69 13.58
1731 Both chr4 112,606,383 112,606,658 miRNA 276 0 0.7 56.18
1731 5' chr4 112,606,478 112,606,658 miRNA 181 0 0.7 56.18
6039 Both chr3 155,125,921 155,126,196 snoRNA C/D 276 0.99 (−) 0 48.87
6039 3' chr3 155,125,921 155,126,101 snoRNAC/D 181 0.99 (−) 0 48.87
8442 Both chr21 19,709,655 19,709,930 snoRNAC/D 276 0.99 (−) 0 9.21
12,375 5' chr19 35,649,281 35,649,461 miRNA 181 0 0.7 12.57
15,215 3' chr17 51,543,077 51,543,257 miRNA 181 0 0.67 12.94
16,666 Both chr3 608,518 608,793 snoRNA C/D 276 0.96 (+) 0 −16.14
16,666 3' chr3 608,518 608,698 snoRNA C/D 181 0.96 (+) 0 −16.14
19,713 Both chr3 7,941,925 7,942,200 miRNA 276 0 0.69 −21.66
19,713 5' chr3 7,942,020 7,942,200 miRNA 181 0 0.69 −21.66
Candidate number indicates the number of the read in our dataset. Extension (Ext) indicates which of the three genomic extractions the classification refers to
the location of the 120 nucleotide extension performed on the original read (3’- 25 nt upstream, 120 nt downstream, 5’ – 120 nt usptream, 25 nt downstream,
Both – 120 nt upstream, 120 nt downstream). Prediction (Pred) indicates the annotation attibuted to the candidate. Positive Fold Change: higher expression in
non-metastasized OSCC; negative Fold Change: higher expression in metastasized OSCC
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Conclusions
The possibility to evaluate the metastatic potential of
OSCC is relevant to the clinical and molecular oncologist
due to the possible asymptomatic development of such
cancer in its early stages. Here we report the identification
of small RNAs linked to the metastatic status of a group
of OSCC, both in tissue and plasma samples. Given the di-
versity of roles of individual miRNAs during the metasta-
sis cascade, including both promoting and suppressive
effects, numerous studies are still necessary for a broad
comprehension of their responsibility in this scenario. For
other small RNA classes, perhaps contributing to the
regulatory network, information is still very scarce.
We corroborate results on two metastasis inhibitors
studied in other cancer types, miR-31 and miR-130b,
and on two metastasis enhancers, miR-181 and miR-296,
in the context of OSCC. We also demonstrate that other
small RNA classes are expressed and should, therefore,
be involved and contribute to the mestastatic phenotype
of this disease.
Methods
Patients and samples
Eighteen patients with OSCC were selected for small
RNA sequencing and 30 patients for the identification of
circulating miRNAs in plasma. Table 1 shows the clinical
and pathological profile of patients. Tumors were staged
according to the Union for International Cancer Control
(UICC)/American Joint Committee on Cancer (AJCC)
staging classification system for HNSCC (7th edition).
All patients were smokers at the time of cancer diagno-
sis and had a history of chronic alcohol use. Primary
tumor tissue samples were collected from patients sub-
mitted to surgical resection of primary tumor at Hospital
das Clinicas and Hospital Heliopolis, in Sao Paulo,
Brazil, and plasma samples were collected from patients
before surgery for tumor resection at Hospital das Clini-
cas and Hospital Heliopolis. All patients provided writ-
ten informed consent, and the research protocol was
approved by review boards of the institutions involved
and by the National Committee of Ethics in Research
(CONEP 1763/05). Tumor samples were snap-frozen in
liquid nitrogen immediately after surgery and stored.
Analysis of hematoxylin and eosin-stained sections by
the study pathologists confirmed at least 70 % of tumor
cells in all OSCC samples.
Total RNA and small RNA fraction isolation from tumor
samples
RNA was prepared from OSCC tissue samples using
AllPrep DNA/RNA/Protein Mini Kit (Qiagen) in com-
pliance with the manufacturer’s protocol. RNA integrity
and miRNA population concentration were assessed
using the RNA 6000 Nano Assay kit and the Small RNA
Assay kit, respectively, with Agilent 2100 Bioanalyzer ac-
cording to the manufacturer's instructions (Agilent
Technologies, Palo Alto, CA).
Small RNA library construction and sequencing
Eighteen small RNA libraries were constructed, one for
each OSCC sample: 10 samples presented lymph node
metastasis at the time of diagnosis and 8 samples did
not present metastasis. Small RNA library construction
followed the SOLiD Total RNA-Seq Kit for Small RNA
Fig. 7 Putative miRNA-candidate mRNA target. Alignment between the predicted mature region of the miRNA-candidate and the 3’ UTR region
of PLEKHA6 (pleckstrin homology domain containing, family A member 6)
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Libraries protocol (Ambion Inc., USA) and the SOLiD
RNA Barcoding System (Ambion Inc., USA) was used
for library multiplexing. One μg of total RNA was used
as template. The SOLiD 5500 Genetic Analyser (Applied
Biosystems, CA, USA) was used to generate 35 bp-long
reads. Default parameters were used at all instances dur-
ing sequencing. Sequencing was performed at GENIAL
(Genome Investigation and Analysis Laboratory), CEFAP-
USP (Centro de Facilidades de Apoio à Pesquisa da
Universidade de São Paulo).
Sequencing data analysis
For miRNA annotation we used the Small RNA Analysis
Tool (RNA2MAP, part of LifeScope™ Genomic Analysis
Solutions, Life Technologies) (LifeScopeTM Genomic
Analysis Software 2.5.1 Applied Biosystems. 2012) [44]
with the following parameters: three color-space mis-
matches within the 'seed sequence' (first 18 bases of the
reads), and six color-space mismatches on the following
positions of the 35 bp reads. Sequences matching tRNA,
rRNA, DNA repeats and adaptor molecules were filtered
out. The remaining reads were matched against the miR-
Base database, release 20 (http://www.mirbase.org/).
Alignments were restricted to 5 hits and, aiming to
identify molecules most likely to represent a miRNA,
multiple hits were only considered when representing
different positions within of a single miRNA family. For
instance, reads could map identically to hsa-mir-24-1 and
hsa-mir-24-2 but for further analysis both such hits were
counted as “hsa-mir-24” and only reads matching the ma-
ture miRNA sequence were counted as known miRNAs.
To visualize better the differential expression in clin-
ical samples we clustered the candidates based on the
global expression patterns. This clustering was per-
formed using the Principal Components Analysis (PCA)
implemented within Partek Genomics Suite (v6.6).
Due to concerns regarding public sharing of patient se-
quence dataset and the anonymity of patients, raw sequen-
cing results are available upon request but, depending on
the scope of the study, it will have to be submitted to the
Ethics Committee approval.
Differential gene expression analysis
For the analysis of small RNA expression levels between
N+ and N0 samples we used the EdgeR Bioconductor
software package [45]. In EdgeR, a Poisson model is used
to account for biological and technical variability, and
empirical Bayes methods are used to assess the degree of
over dispersion across transcripts. For this analysis we
included only reads with at least 10 counts per sample,
and which presented the same direction in expression
levels (either up or down regulated) across at least half
the samples belonging to each group. Molecules that
presented at least a 2-fold difference in expression
between the two groups and which were regulated in at
least half the samples from each group were considered
differentially expressed. Additionally, differential expres-
sion was considered statistically significant when FDR
(False Discovery Rate) corrected p value was < 0.05.
Detection of circulating miRNAs in plasma
Plasma was separated from 5 ml of EDTA whole blood
using a centrifugation step of 3600 rpm for 10 min. The
miRNA population was isolated from 200 μl of plasma
using the miRCURY RNA Isolation Kit – Biofluids (Exi-
qon), following the instructions provided in the manual.
For the identification of miRNAs we used the Locked
Nucleic Acid (LNA™)-based miRNA qPCR platform
from Exiqon. Briefly, 4 μl of RNA were used for cDNA
synthesis using MiRCURY LNA™ Universal RT kit
microRNA PCR. The cDNA was diluted following the
manufacturer’s protocol and real time PCR was carried
out using specific, pre-defined microRNA primer pairs
and the ExiLENT SYBR Green Master Mix (Exiqon),
following the manufacturer’s protocol, using a ABI7500
instrument (Lifetechnologies). MiRNAs evaluated in
plasma were those identified as differentially expressed be-
tween N+ and N0 tumors following small RNA sequen-
cing in this study but which had been previously detected
in plasma by a large scale study [38]: miR-20b (Exiqon
204755), miR-30a (Exiqon 205695), miR-31 (Exiqon
204236), miR-106a (Exiqon 204563), miR-130b (Exiqon
204317), miR-139 (Exiqon 205874), miR-296 (Exiqon
204436), miR-301 (Exiqon 204687), miR-335 (Exiqon
204151), miR-551b (Exiqon 204067). As a reference gene
for data normalization we used miR-93 (Exiqon 204715),
as suggested by the manufacturer and validated in our
samples as stably expressed.
Relative quantification of miRNA expression levels in tissue
samples using Real Time-PCR
To validate the sequencing data, 3 miRNAs were sub-
jected to quantitative Real Time-PCR using the Locked
Nucleic Acid (LNA™)-based miRNA qPCR platform
from Exiqon. Briefly, 5 ng of RNA were used for cDNA
synthesis using MiRCURY LNA™ Universal RT kit
microRNA PCR. Real time PCR was carried out using
specific, pre-defined miRNA primer pairs and the Exi-
LENT SYBR Green Master Mix (Exiqon), following the
manufacturer’s protocol and an ABI7500 instrument
(Life Technologies). The expression data was normalized
to the small RNA SNORD48 expression levels (Exiqon
203903) and for relative quantification we used the com-
parative ΔCt method [46].
Identification of known small RNAs other than miRNAs
In order to search for small RNAs other than miRNAs
we took the trimmed and filtered sequences that did not
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match miRBase (i.e., 35 nt long sequences) and matched
them to sequences downloaded from public databases
containing small RNA sequences: Cogemir [47]; Deep-
Base [48]; piRNABank [49]; smiRNADB [50]; RNAdb
[51]; CONDOR [52]; fRNAdb [53], microRNA.org [54];
miRNAMap [55]; NONCODE [56] and UCSC Genome
Browser human miRNAs/snoRNA [57].
Hits were restricted to those with 100 % similarity,
100 % coverage of our query or of the subject sequences
of the databases, and with identical coordinates in the
genome.
Identification of novel differentially expressed small RNA-
like molecules
Sequences that did not match known miRNAs or other
small RNAs could be part of novel small RNA-like mole-
cules. In order to evaluate this possibility we used a dis-
covery process based on ab initio classification, similarity
search and structural search.
If our differentially expressed reads corresponded to
mature miRNAs, they should be part of a larger precursor
miRNAs. Characterizing this putative precursor miRNA
was the goal of our ab initio classification and structural
Fig. 8 MicroRNA precursor length of sequences deposited in miRBase v20. The bar chart shows the frequency of lengths of human miRNA
precursors deposited in miRBase v.20
Fig. 9 Position of mature miRNAs within their precursor molecules. The bar chart shows the frequency of first positions (first nucleotide) of a
mature miRNA sequence within its precursor molecule. We used the miRBase v. 20 for this evaluation
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search. At the time of this publication miRNA precursor
sequences deposited in miRBase v.20 presented a max-
imum of 180 nucleotides in length (Fig. 8) and mature
sequences mapped mostly from the 5’ end to the middle
of the molecule (Fig. 9). Considering this information, we
mapped our reads in the genome and extracted 3 candi-
date sequences for each read: one 180 nucleotide se-
quence that extended the original read an additional 25
nucleotides to the 3’ and 120 to the 5’ end in order to
consider mature sequences matching to the 5’ of the
precursor sequence; one 180 nucleotide sequence that
extended the original read an additional 120 nucleotides
to the 3’ and 25 to the 5’ end, accounting for mature se-
quences matching the 3’ end of the precursor sequence;
and one that extended the original read 120 nucleotides
at each side, accounting for mature sequences matching
around the center of the precursor molecules. We
named these extended sequences miRNA-candidates.
We extracted the three candidates from each original
read due to the negative impact extra nucleotides can
have in ab initio prediction methods based on previous
folding.
To detect candidates we applied a pipeline that in-
cluded: (i) similarity search against the sequences from
the 11 databases described in the previous section; (ii)
structural search performed against the RFAM [58] using
the Infernal for RNA alignment (INFERence of RNA
Alignment), version 0.81 [59] with the default parameters
and the recommended bitscore cutoff value of 25; (iii) ab
initio classification using SnoScan [60] with the recom-
mended cutoff value; SnoReport [61] with a cutoff value
of 0.90 and HHMMIR [62] using the BaumWelch trained
model and the recommended threshold of 0.71. To use
HHMMIR we folded the candidates using RNAfold [63].
After excluding all candidates where the orginal read
mapped to known ncRNAs of other families, we consid-
ered putative miRNAs those candidate sequences that
were classified as miRNAs by RFAM, or those that were
classified as miRNAs by HMMIR and did not present
positive scores by SnoScan or SnoReport.
Additionally, we required that strong miRNA-
candidates should have the original read mapped to the
stem region of the predicted secondary structure. When
this was the case we looked for a possible mature se-
quence within the sequenced read using default parame-
ters from the algorithm MatureBayes [64]. Mature
sequences were then aligned to the 3’ UTR region of hu-
man genes obtained from UTRDB [65] in order to find
putative mRNA targets using the miRanda algorithm
[66]. Different algorithms come up with a different selec-
tion of targets [67]. miRanda was chosen since it is the
same algorithm used by mirRBase [68], our primary
source of miRNA information in this work, and it has
been shown to perform better than other algorithms
such as TargetScan and RNAHybrid in terms of specifi-
city in a review tackling this issue [69].
Additional files
Additional file 1: Sequencing results from 8 non-metastatic tumor
samples and 10 metastatic tumor samples. We used miRBase v.20 and
human genome hg19 reference sequences for mapping. Number of
reads should be multiplied by 105.
Additional file 2: Complete set of detected mature miRNAs and
correspondent read counts in non-metastatic tumor samples. We
used miRBase v.20 as reference for miRNA identification. Read counts are
raw numbers (not normalized).
Additional file3: Complete set of detected mature miRNAs and
correspondent read counts in metastatic tumor samples. We used
miRBase v.20 as reference for miRNA identification. Read counts are raw
numbers (not normalized).
Additional file 4: Most expressed miRNAs in non-metastatic tumor
samples. The graph shows the most expressed miRNAs per sample
(x-axis) and correspondent read counts (y-axis). Numbers on top of each
bar correspond to the cumulative percentage considering the total number
of read counts per sample.
Additional file 5: Most expressed miRNAs in metastatic tumor
samples. The graph shows the most expressed miRNAs per sample
(x-axis) and correspondent read counts (y-axis). Numbers on top of each
bar correspond to the cumulative percentage considering the total
number of read counts per sample.
Additional file 6: Validation of miRNA expression levels in an
additional set of tumor tissue samples. Average expression levels
were considered in this figure and fold-change compares N0 and
N+ samples. Negative results indicate over-expression in N+ samples.
Additional file 7: Complete set of small RNAs other than miRNA
identified in tumor samples, with specific type report in non-coding
RNA databanks. For the annotation of small RNAs we used BLAST
search against available databanks of non-coding RNA sequences.
Additional file 8: Complete set of small RNAs other than miRNA
identified in tumor samples with evidences from ab initio prediction
reported in non-coding RNA databanks. The annotation procedure of
this set of small RNAs used BLAST search against available databanks of
non-coding RNA sequences but reports showed only evidences from ab
initio prediction.
Additional file 9: Expression levels of all small RNAs other than
miRNA identified in tumor samples. The annotation procedure of this
set of small RNAs used BLAST search against available databanks of
non-coding RNA sequences but reports showed only evidences from ab
initio prediction.
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